Nurix Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (Nasdaq: NRIX) on March 11, 2025. The filing discloses a corporate governance event involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
On March 11, 2025, the Board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., as a director and member of the Clinical and Commercialization Committee, effective immediately. Dr. Baynes serves as a Class II director with a term expiring at the 2025 annual meeting of stockholders.
Compensation and Equity Arrangements
- Cash Retainer: Dr. Baynes will receive a pro rata portion of the $50,000 annual director retainer and a pro rata portion of the $5,000 annual committee retainer for the remainder of the fiscal year ending November 30, 2025.
- Initial Equity Award: A stock option to purchase 50,000 shares of common stock was granted on March 11, 2025. The exercise price equals the closing sale price on the grant date. The award vests monthly over three years, contingent on continued service.
- Annual Equity Award: Dr. Baynes is eligible for customary annual equity compensation consisting of a stock option to purchase 25,000 shares, vesting on the earlier of the next annual meeting or one year from the grant date.
- Acceleration: Both the Initial Award and Annual Awards accelerate in full upon the consummation of a Corporate Transaction.
Risks and Contingencies
The filing states there are no family relationships between Dr. Baynes and other directors or officers, and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K. The company has executed a standard indemnification agreement with Dr. Baynes.
Investor Verification Checklist
- Verify the closing stock price on March 11, 2025, to determine the exercise price of the 50,000 share Initial Award.
- Review the Company's 2020 Equity Incentive Plan for the specific definition of "Corporate Transaction" triggering award acceleration.
- Confirm the exact vesting schedule and any potential forfeiture conditions in the Non-Employee Director Compensation Program.
- Check the press release (Exhibit 99.1) for additional biographical details on Dr. Baynes' qualifications.